BIOA|EPS -$2.24|Rev $9.0M|Net Loss $80.6MCompany Overview
BioAge Labs is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases by targeting human aging biology.
Key Financial Figures
For the year ended December 31, 2025, the company reported a collaboration revenue of $9.0 million. The net loss per share, representing EPS, was $(2.24). The total net loss for the year was $80.6 million.
Additional Financial Insights
Research and development expenses reached $73.9 million in 2025. As of the end of the year, BioAge maintained approximately $285.1 million in cash, cash equivalents, and marketable securities.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.